Progen scores half-million manufacturing deal
11 April, 2002 by Pete YoungUS biotech Lipid Sciences has signed a $500,000 manufacturing pact with Progen Industries, boosting Progen's already-thriving contract drug manufacturing arm.
Qld government moves to shore up R&D framework
11 April, 2002 by Pete YoungQueensland's Cabinet has kicked off a sweeping effort to set in place a long-term R&D framework in place for emerging industries.
Vita Life goes after former MD
11 April, 2002 by Tanya HollisVita Life Sciences is seeking recompense from its former managing director over what it says was a costly breach of agreement.
Chairman, board members resign from Peptech
11 April, 2002 by Daniella GoldbergThe three newest members of the board of Sydney biotech Peptech have resigned, after shareholders threatened to call an extraordinary general meeting to have them removed.
Nelson appoints science journo as advisor
10 April, 2002 by Iain ScottThe Federal Health Minister, Dr Brendan Nelson, has appointed researcher turned science writer Dr Thomas Barlow as his science advisor.
Baby boomers to benefit from new research centre
10 April, 2002 by Daniella GoldbergBaby boomers will reap the benefits of a new medical research institute opened today at Concord Hospital, in western Sydney.
Vic govt decision could spell fate of Amrad board
10 April, 2002 by Tanya HollisThe fate of Amrad Corporation's beleaguered board could fall in the lap of Victorian Treasurer and Innovation Minister John Brumby.
Give programs time to mature: Radke
09 April, 2002 by Tanya HollisCalls for the government to initiate further commercialisation programs were premature, according to Commonwealth industry body Biotechnology Australia.
Separation anxiety: drawing the line between funding and commercialisation
09 April, 2002 by Tanya HollisA debate is emerging over where to draw the line on use of basic research funding sparked by the wholesale push towards commercialisation of Australian research.
Entrepreneur CEO to take BioSignal to market
09 April, 2002 by Daniella GoldbergSydney start-up BioSignal has appointed a CEO, Swedish entrepreneur Michael Oredsson.
Iatia makes an auspicious ASX debut
09 April, 2002 by Tanya HollisIt might not have been quite as exhilarating as his former life as a fighter pilot, but Iatia managing director Philippe Cussinet said the float of his company today was pretty exciting nonetheless.
Global patent tests would cut IP costs
05 April, 2002 by Tanya HollisPatent examinations should be standardised across the world to make appropriate intellectual property protection more affordable.
It's not just heaven that's missing an angel
05 April, 2002 by Melissa TrudingerThere is a major lack of angel investment in the biotech industry in Australia, according to investment groups such as Tinshed and Rothschild Bioscience.
Positive outlook for biotech in latest Deloittes index
05 April, 2002 by Iain ScottThe latest Deloitte index of companies on the Australian Stock Exchange's Healthcare and Biotechnology Index has painted a picture of increasing investor confidence in smaller stocks.
Biotech boosted at Invest Australia
04 April, 2002 by Daniella GoldbergFederal government agency Invest Australia's biotechnology team will quadruple in size after undergoing a major restructure to be completed July 1 this year.
